---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-013290"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:45:56.704221+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences reports Q4 2025 net loss of $4.0M, cash $4.7M, advances EB-003 towards IND

## Summary
- Net loss of $4.0M in Q4 2025 ($6.12 per share) vs $3.2M loss ($58.06 per share) in Q4 2024; per-share impacted by 1:12 reverse split.
- Cash $4.7M at Dec 31; raised $12.2M in gross proceeds during FY 2025; subsequently raised $1.5M (Jan 2026) and $1.45M (Feb 2026).
- EB-003 showed positive preclinical results in chronic depression and PTSD models; preparing IND submission to FDA for first-in-human trial.
- PGR petition by Gilgamesh/AbbVie against Enveric patent withdrawn; patent covers bretisilocin (GM-2505) acquired by AbbVie for $1.2B.

## SEC filing metadata
- accession: 0001493152-26-013290
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/0001493152-26-013290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-013290
- JSON: https://secwatch.observer/filing/0001493152-26-013290.json
- Plain text: https://secwatch.observer/filing/0001493152-26-013290.txt

## Key facts
- Earnings Releases
  Enveric Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
  - Period: the fourth quarter and year ended December 31, 2025
  - Result: reported results
  source text: Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the fourth quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/0001493152-26-013290-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.